autophilic peptide conjuagted rituximab (InNexus)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameautophilic peptide conjuagted rituximab (InNexus)

Drug Alias Nameanti-CD20 monoclonal antibodies (InNexus)anti-CD20 monoclonal antibodies (InNexus)DXLr-120DXL-625

ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsArthritis, RheumatoidLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesInNexus Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesInNexus Biotechnology Inc

Active IndicationsN/A

Inactive IndicationsArthritis, RheumatoidLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A